These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 11026976)
1. Vasoprotection as neuroprotection for the optic nerve. Harris A; Ciulla TA; Kagemann L; Zarfati D; Martin B Eye (Lond); 2000 Jun; 14 ( Pt 3B)():473-5. PubMed ID: 11026976 [No Abstract] [Full Text] [Related]
2. [Neuroprotection in glaucoma]. Stefan C; Melinte-Dumitrica D; Selaru D; Musat O; Zemba M; Serghiescu I Oftalmologia; 2010; 54(2):7-10. PubMed ID: 20827905 [TBL] [Abstract][Full Text] [Related]
3. Neuroprotection and regeneration in glaucoma. Levin LA Ophthalmol Clin North Am; 2005 Dec; 18(4):585-96, vii. PubMed ID: 16314221 [TBL] [Abstract][Full Text] [Related]
4. Neuroprotection by sodium channel blockade with phenytoin in an experimental model of glaucoma. Hains BC; Waxman SG Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4164-9. PubMed ID: 16249495 [TBL] [Abstract][Full Text] [Related]
5. [Neurodegeneration and neuroprotection]. Schmidt KG Ophthalmologe; 2004 Nov; 101(11):1059-61. PubMed ID: 15449095 [No Abstract] [Full Text] [Related]
6. Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation. Schwartz M; London A Prog Brain Res; 2008; 173():375-84. PubMed ID: 18929122 [TBL] [Abstract][Full Text] [Related]
7. New conceptual approaches for pharmacological neuroprotection in glaucomatous neuronal degeneration. Neufeld AH J Glaucoma; 1998 Dec; 7(6):434-8. PubMed ID: 9871868 [No Abstract] [Full Text] [Related]
8. Neuroprotection: a new treatment modality for glaucoma? Schwartz M; Yoles E Curr Opin Ophthalmol; 2000 Apr; 11(2):107-11. PubMed ID: 10848215 [TBL] [Abstract][Full Text] [Related]
9. Neuroprotection: the next breakthrough in glaucoma? Proceedings of the Third Annual Optic Nerve Rescue and Restoration Think Tank. Chew SJ; Ritch R J Glaucoma; 1997 Aug; 6(4):263-6. PubMed ID: 9264307 [No Abstract] [Full Text] [Related]
10. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Yoles E; Wheeler LA; Schwartz M Invest Ophthalmol Vis Sci; 1999 Jan; 40(1):65-73. PubMed ID: 9888428 [TBL] [Abstract][Full Text] [Related]
12. [Prospects in the medical treatment of glaucomatous neuropathy. Basics of neuroprotection]. Detry-Morel M J Fr Ophtalmol; 1999 Feb; 22(1):122-34. PubMed ID: 10221206 [No Abstract] [Full Text] [Related]
13. Neuroprotection in glaucoma - Is there a future role? Baltmr A; Duggan J; Nizari S; Salt TE; Cordeiro MF Exp Eye Res; 2010 Nov; 91(5):554-66. PubMed ID: 20800593 [TBL] [Abstract][Full Text] [Related]
16. Clinical trials for glaucoma neuroprotection are not impossible. Quigley HA Curr Opin Ophthalmol; 2012 Mar; 23(2):144-54. PubMed ID: 22249238 [TBL] [Abstract][Full Text] [Related]
17. In glaucoma, should enthusiasm about neuroprotection be tempered by the experience obtained in other neurodegenerative disorders? Haefliger IO; Fleischhauer JC; Flammer J Eye (Lond); 2000 Jun; 14 ( Pt 3B)():464-72. PubMed ID: 11026975 [TBL] [Abstract][Full Text] [Related]
18. Strategies for neuroprotection. Girkin CA J Glaucoma; 2001 Oct; 10(5 Suppl 1):S78-80. PubMed ID: 11890287 [TBL] [Abstract][Full Text] [Related]
19. Glaucoma neuroprotection: What is it? Why is it needed? Weinreb RN Can J Ophthalmol; 2007 Jun; 42(3):396-8. PubMed ID: 17508033 [TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effect of intravitreal cell-based glucagon-like peptide-1 production in the optic nerve crush model. Zhang R; Zhang H; Xu L; Ma K; Wallrapp C; Jonas JB Acta Ophthalmol; 2011 Jun; 89(4):e320-6. PubMed ID: 21470377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]